FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Immunol Immunopathol / Determination of equid herpesvirus 1-specific, CD8+, cytotox...
Veterinary immunology and immunopathology1999; 70(1-2); 43-54; doi: 10.1016/s0165-2427(99)00037-9

Determination of equid herpesvirus 1-specific, CD8+, cytotoxic T lymphocyte precursor frequencies in ponies.

Abstract: The frequency of antigen-specific, genetically restricted cytotoxic T lymphocyte precursors (CTLp) was measured in peripheral blood mononuclear cells (PBMC) of ponies before and after infection with equid herpesvirus 1 (EHV1). Split-well limiting dilution analysis (LDA) was developed to measure CTLp frequency using EHV1-infected 51Cr-labelled lymphoblasts as targets. Extensive characterisation showed that recombinant human interleukin-2, autologous antigen presenting cells and equine serum containing virus neutralising antibody were necessary for maturation of CTLp into effector CTL in vitro. CTLs were not induced when the equine serum (containing VN antibody) was replaced with either foetal calf serum or foetal equine serum (without VN antibody), or seronegative equine serum. CTLp frequency decreased significantly when CD8+ lymphocytes were depleted from the induction cultures. There was good inter- and intra-assay reproducibility using both fresh and recovered cryopreserved PBMC. Both EHV1 and EHV4 could be used to induce effector CTL which lysed EHV1-infected target cells. CTLp frequencies were measured in 2 groups of ponies: Group 1 consisted of two ponies (approx. 9 years old), which had multiple previous experimental infections with EHV1; Group 2 comprised five young (1-2 years) and two older (7 years) ponies which had presumed natural exposure to EHV1/EHV4 but no previous experimental infections. The results showed that CTLp frequencies were higher in the ponies of Group 1 compared with the others. Moreover, ponies with the higher CTLp frequencies were better protected against re-challenge infection with EHV1, showing reduced or absent clinical and virological signs. Consequently, measurement of EHV1-specific CTLp frequency is a potential in vitro correlate of immunity which may be useful for screening new vaccines in horses before embarking upon challenge protection studies to confirm efficacy.
Get Full Text
Publication Date: 1999-10-03 PubMed ID: 10507286DOI: 10.1016/s0165-2427(99)00037-9Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research observed the number of antigen-specific, cytotoxic T lymphocyte precursors (CTLp) in ponies before and after infection with equine herpesvirus 1 (EHV1). It found that animals with a higher CTLp frequency had lower or nonexistent clinical and virological signs when re-infected with EHV1, suggesting that the measurement of EHV1-specific CTLp frequency may be a useful way to screen new vaccines in horses.

Methods

  • The research team developed a split-well limiting dilution analysis (LDA) to measure the frequency of CTLp. This method involved using EHV1-infected 51Cr-labelled lymphoblasts as targets.
  • Detailed characterisation indicated that recombinant human interleukin-2, as well as autologous antigen presenting cells and equine serum with virus neutralising antibody, were needed for the maturation of CTLp into effector CTL in vitro.
  • The team confirmed that CTLs were not induced when the equine serum was replaced with infected or disease-negative equine serum or foetal calf serum.
  • If CD8+ lymphocytes were removed from the induction cultures, the CTLp frequency significantly decreased.

Results

  • PBMCs, fresh and those recovered after cryopreservation, showed good inter- and intra-assay reproducibility.
  • Both EHV1 and EHV4 could induce effector CTL, which then lysed EHV1-infected target cells.
  • Two groups of ponies were tested. Group 1 had two ponies about 9 years old, which had been infected with EHV1 multiple times. Group 2 consisted of five young (1-2 years) and two older (7 years) ponies which had likely natural exposure to EHV1/EHV4 but no previous experimental infections.
  • The results showed that CTLp frequencies were higher in Group 1 ponies.
  • Ponies with higher CTLp frequencies showed reduced or absent clinical and virological signs when re-infected with EHV1.

Conclusions

  • These findings suggest that measuring EHV1-specific CTLp frequency is a potential in vitro correlate of immunity.
  • This method could be useful for screening new vaccines in horses before starting protection studies to confirm their efficiency.

Cite This Article

APA
O'Neill T, Kydd JH, Allen GP, Wattrang E, Mumford JA, Hannant D. (1999). Determination of equid herpesvirus 1-specific, CD8+, cytotoxic T lymphocyte precursor frequencies in ponies. Vet Immunol Immunopathol, 70(1-2), 43-54. https://doi.org/10.1016/s0165-2427(99)00037-9

Publication

Veterinary immunology and immunopathology
ISSN: 0165-2427
NlmUniqueID: 8002006
Country: Netherlands
Language: English
Volume: 70
Issue: 1-2
Pages: 43-54

Researcher Affiliations

O'Neill, T
  • Centre for Preventive Medicine, Animal Health Trust, Kentford, Suffolk, UK.
Kydd, J H
    Allen, G P
      Wattrang, E
        Mumford, J A
          Hannant, D

            MeSH Terms

            • Animals
            • CD8 Antigens
            • Female
            • Herpesviridae Infections / immunology
            • Herpesviridae Infections / prevention & control
            • Herpesviridae Infections / veterinary
            • Herpesvirus 1, Equid / immunology
            • Horse Diseases / immunology
            • Horse Diseases / prevention & control
            • Horses / immunology
            • Horses / virology
            • Humans
            • Male
            • T-Lymphocytes, Cytotoxic / immunology
            • T-Lymphocytes, Cytotoxic / virology
            • Viral Vaccines

            Citations

            This article has been cited 16 times.
            1. Zarski LM, Vaala WE, Barnett DC, Bain FT, Soboll Hussey G. A Live-Attenuated Equine Influenza Vaccine Stimulates Innate Immunity in Equine Respiratory Epithelial Cell Cultures That Could Provide Protection From Equine Herpesvirus 1. Front Vet Sci 2021;8:674850.
              doi: 10.3389/fvets.2021.674850pubmed: 34179166google scholar: lookup
            2. Laval K, Poelaert KCK, Van Cleemput J, Zhao J, Vandekerckhove AP, Gryspeerdt AC, Garré B, van der Meulen K, Baghi HB, Dubale HN, Zarak I, Van Crombrugge E, Nauwynck HJ. The Pathogenesis and Immune Evasive Mechanisms of Equine Herpesvirus Type 1. Front Microbiol 2021;12:662686.
              doi: 10.3389/fmicb.2021.662686pubmed: 33746936google scholar: lookup
            3. Zarski LM, Giessler KS, Jacob SI, Weber PSD, McCauley AG, Lee Y, Soboll Hussey G. Identification of Host Factors Associated with the Development of Equine Herpesvirus Myeloencephalopathy by Transcriptomic Analysis of Peripheral Blood Mononuclear Cells from Horses. Viruses 2021 Feb 24;13(3).
              doi: 10.3390/v13030356pubmed: 33668216google scholar: lookup
            4. Zarski LM, Weber PSD, Lee Y, Soboll Hussey G. Transcriptomic Profiling of Equine and Viral Genes in Peripheral Blood Mononuclear Cells in Horses during Equine Herpesvirus 1 Infection. Pathogens 2021 Jan 7;10(1).
              doi: 10.3390/pathogens10010043pubmed: 33430330google scholar: lookup
            5. Attili AR, Colognato R, Preziuso S, Moriconi M, Valentini S, Petrini S, De Mia GM, Cuteri V. Evaluation of Three Different Vaccination Protocols against EHV1/EHV4 Infection in Mares: Double Blind, Randomized Clinical Trial. Vaccines (Basel) 2020 Jun 1;8(2).
              doi: 10.3390/vaccines8020268pubmed: 32492841google scholar: lookup
            6. Oladunni FS, Horohov DW, Chambers TM. EHV-1: A Constant Threat to the Horse Industry. Front Microbiol 2019;10:2668.
              doi: 10.3389/fmicb.2019.02668pubmed: 31849857google scholar: lookup
            7. Schnabel CL, Wimer CL, Perkins G, Babasyan S, Freer H, Watts C, Rollins A, Osterrieder N, Wagner B. Deletion of the ORF2 gene of the neuropathogenic equine herpesvirus type 1 strain Ab4 reduces virulence while maintaining strong immunogenicity. BMC Vet Res 2018 Aug 22;14(1):245.
              doi: 10.1186/s12917-018-1563-4pubmed: 30134896google scholar: lookup
            8. Bergmann T, Moore C, Sidney J, Miller D, Tallmadge R, Harman RM, Oseroff C, Wriston A, Shabanowitz J, Hunt DF, Osterrieder N, Peters B, Antczak DF, Sette A. The common equine class I molecule Eqca-1*00101 (ELA-A3.1) is characterized by narrow peptide binding and T cell epitope repertoires. Immunogenetics 2015 Nov;67(11-12):675-89.
              doi: 10.1007/s00251-015-0872-zpubmed: 26399241google scholar: lookup
            9. Laval K, Favoreel HW, Poelaert KC, Van Cleemput J, Nauwynck HJ. Equine Herpesvirus Type 1 Enhances Viral Replication in CD172a+ Monocytic Cells upon Adhesion to Endothelial Cells. J Virol 2015 Nov;89(21):10912-23.
              doi: 10.1128/JVI.01589-15pubmed: 26292328google scholar: lookup
            10. Goodman LB, Wimer C, Dubovi EJ, Gold C, Wagner B. Immunological correlates of vaccination and infection for equine herpesvirus 1. Clin Vaccine Immunol 2012 Feb;19(2):235-41.
              doi: 10.1128/CVI.05522-11pubmed: 22205656google scholar: lookup
            11. Mealey RH, Sharif A, Ellis SA, Littke MH, Leib SR, McGuire TC. Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes. Virology 2005 Aug 15;339(1):110-26.
              doi: 10.1016/j.virol.2005.05.025pubmed: 15979679google scholar: lookup
            12. Castillo-Olivares J, Wieringa R, Bakonyi T, de Vries AA, Davis-Poynter NJ, Rottier PJ. Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain. J Virol 2003 Aug;77(15):8470-80.
              doi: 10.1128/jvi.77.15.8470-8480.2003pubmed: 12857916google scholar: lookup
            13. Pradhan SS, Balena V, Bera BC, Anand T, Khetmalis R, Madhwal A, Kandasamy S, Pavulraj S, Bernela M, Mor P, Tripathi BN, Virmani N. Multiple Gene Deletion Mutants of Equine Herpesvirus 1 Exhibit Strong Protective Efficacy Against Wild Virus Challenge in a Murine Model. Vaccines (Basel) 2025 Jan 8;13(1).
              doi: 10.3390/vaccines13010045pubmed: 39852824google scholar: lookup
            14. Holmes CM, Wagner B. Characterization of Nasal Mucosal T Cells in Horses and Their Response to Equine Herpesvirus Type 1. Viruses 2024 Sep 25;16(10).
              doi: 10.3390/v16101514pubmed: 39459849google scholar: lookup
            15. Giessler KS, Goehring LS, Jacob SI, Davis A, Esser MM, Lee Y, Zarski LM, Weber PSD, Hussey GS. Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses. J Gen Virol 2024 May;105(5).
              doi: 10.1099/jgv.0.001987pubmed: 38767608google scholar: lookup
            16. Pusterla N, Dorman DC, Burgess BA, Goehring L, Gross M, Osterrieder K, Soboll Hussey G, Lunn DP. Viremia and nasal shedding for the diagnosis of equine herpesvirus-1 infection in domesticated horses. J Vet Intern Med 2024 May-Jun;38(3):1765-1791.
              doi: 10.1111/jvim.16958pubmed: 38069548google scholar: lookup
            Subscribe to our newsletter
            Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.